Across TCGA pan-cancer cohorts, LUZP2 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated LUZP2 data layer compared with 5 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LUZP2 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated LUZP2 expression acts as an unfavorable survival marker, although some lineages such as LUSC and LGG show a favorable association.
LUSC, UVM, and ACC are the cancer types where LUZP2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.